![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Farzaneh F, Honarvar Z, Yaraghi M, Yaseri M, Arab M, Hosseini M, et al. 2014. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iranian Red Crescent Medical Journal 16:e17185.
- Hull Richard P, Goldsmith David JA. 2008. Nephrotic syndrome in adults. British Medical Journal 336:1185.
- Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. 2003. Cancer antigen 125 associated with multiple benign and malignant pathologies. Annals of Surgical Oncology 10:150–154.
- National Institute for Health and Care Excellence. 2011. NICE Clinical Guidance: the recognition and initial management of ovarian cancer. [CG122]. London: National Institute for Health and Care Excellence.
- Silberstein LB, Rosenthal AN, Coppack SW, Noonan K, Jacobs IJ. 2001. Ascites and a raised serum Ca 125-confusing combination. Journal of the Royal Society of Medicine 94:581–582.
- Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, et al. 2002. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecologic Oncology 85:108–113.